Centene's Chart Presents a Confusing Picture
CNC has been a hard stock to trade and to analyze
Speculative Mind Medicine Could Double or Triple From Here
My recommendation is not for the shy, timid, or new trader.
CRISPR Therapeutics Is Editing Out Its Correction
Investors can now look to buy shares of this biotech firm.
PerkinElmer Should Continue Its Rally to Record Highs in the Months Ahead
Traders should approach PKI from the long side at current levels.
AstraZeneca Is Moving the Needle
This drugmaker is making a historic upside breakout. Let's check the charts.
Biogen's Japanese Partner on Alzheimer's Drug Set for Gains
Eisai is working on another promising drug candidate to combat Alzheimer's disease, and will benefit from a split of the profits for Aduhelm.
Moderna's Charts Are Bullish and Pointed Higher
Here's the area where I would like to go long MRNA.
Is It Too Late to Buy Progyny?
A Real Money subscriber asks. We answer.
As America Grows Older, So Does the Appeal of This Dividend REIT
Omega Healthcare offers a 7% yield and promise of growth.
An Updated Technical Strategy for HCA Healthcare
Let's review the charts and indicators.